Maintenance immunotherapy in advanced urothelial cancer
Advanced urothelial carcinoma usually responds to platinum-based chemotherapy (CT), although overall survival (OS) and progression-free survival are typically short. Immunotherapy is a promising treatment strategy, but the first-line benefits in platinum-eligible patients are limited, and its combin...
Wedi'i Gadw mewn:
| Prif Awduron: | , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Permanyer
2022-07-01
|
| Cyfres: | Gaceta Mexicana de Oncología |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.gamo-smeo.com/frame_esp.php?id=323 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|